Glioblastoma

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

TVAX Biomedical's randomized phase 2/3 study of TVI-Brain-1 plus standard therapy versus standard therapy alone in newly diagnosed MGMT-unmethylated GBM is now active, not recruiting — enrolled and in follow-up. The design is a closed autologous loop: a vaccine built from the patient's resected tumor expands neoantigen-specific effector T cell precursors, which are harvested from blood, stimulated and expanded ex vivo, then reinfused. Reaching phase 2/3 in GBM places this among the more advanced neoantigen-directed adoptive T cell programs, with randomized, standard-of-care-controlled data as the bar.

Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas

Beijing Tiantan Hospital is running a single-center, open-label phase 1 of ZSNeo-DC1.1, an autologous, genetically unmodified dendritic cell vaccine loaded with multiple tumor neoantigen peptides, in roughly 15 adults with recurrent or progressive WHO grade III-IV glioma after reoperation. The protocol uses a fixed 1×10^7-cell dose, two immunization schedules, and a DLT window running to 21 days after the third injection, starting with a six-subject dose confirmation stage. It adds a China-based safety and preliminary efficacy datapoint for personalized DC vaccines in recurrent high-grade glioma post-standard treatment.

Publisher Correction: Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.

Immune Modulatory DC Vaccine Against Brain Tumor

[NOT_YET_RECRUITING · PHASE1 · Shenzhen Geno-Immune Medical Institute] This study is designed to treat patients who have been diagnosed with brain cancer, including glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). The treatment uses immunomodulatory vaccine generat…

The BioPharm Brief: Cancer, Personalized - BioPharm International

This week’s BioPharm Brief covers positive phase 3 melanoma results for Merck and Moderna’s individualized neoantigen therapy, a personalized cancer vaccine manufacturing platform entering clinical use, and a new brain-penetrant antibody approach for glioblastoma. Welcome to The …

Personalized neoantigen-pulsed autologous dendritic cells in newly-diagnosed glioblastoma: a phase Ib trial - Nature

A single-arm phase Ib trial of ZSNeo-DC, a personalized neoantigen-pulsed autologous dendritic cell therapy, showed good tolerability in newly-diagnosed glioblastoma patients. The treatment was well-tolerated with predominantly grade 1 or 2 adverse events, and secondary endpoints revealed a median progression-free survival of 16.2 months. This data supports the clinical viability of DC-based personalized vaccines as an adjuvant to standard radio-chemotherapy.

Neoantigen-based multi-epitope vaccine designing against glioblastoma using reverse vaccinology and immunoinformatic approaches.

One of the primary factors in the development of cancer is the accumulation of genetic mutations. Some of these genetic mutations result in the emergence of unique antigens called neoantigens. These neoantigens are perceived as non-self by T cells, making them prime targets for c…

Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications.

A review of glioblastoma immunobiology highlights a critical disconnect between murine models and human tumors: patient GBM is enriched for clonally expanded granzyme K+ T cells, whereas standard mouse models show exhausted T cells. This distinction suggests that current preclinical models may misrepresent the targetable neoantigen landscape. The authors argue that harnessing tumor-selective T cells via neoantigen vaccines or adoptive transfer requires a refined focus on these specific human TIL profiles.